Anota, Amélie
Pozet, Astrid http://orcid.org/0000-0003-4371-1112
Lemasson, Hervé
Cotté, Francois-Emery
Falcoz, Antoine
Eberst, Guillaume
Mouillet, Guillaume
Guerzider, Stéphane
Charton, Émilie
Westeel, Virginie
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Accepted: 7 July 2021
First Online: 20 July 2021
Declarations
:
: Dr Amélie Anota reports receiving personal fees from Astra Zeneca, Bristol Myers Squibb and Roche, and travel expenses from Astra Zeneca, Bristol Myers Squibb, Hospira, Novartis and Pfizer. François-Emery Cotté and Hervé Lemasson are Bristol Myers Squibb employees, pharmaceutical company providing ICIs. Dr Emilie Charton reports receiving consulting fees from Roche and travel expenses from Bristol Myers Squibb. Dr Guillaume Mouillet reports remuneration for serving as a Novartis and Pfizer advisory board member, speaker honoraria from Bristol Myers Squibb, IPSEN and Pfizer, a grant from Novartis and travel expenses from IPSEN and Pfizer. Dr Guillaume Eberst reports receiving speaker honoraria and congress funding from Astra Zeneca, Bristol Myers Squibb, Lilly Oncology, MSD and Pfizer. Pr Virginie Westeel reports personal fees from Amgen, Astra Zeneca, Bristol Myers Squibb, MSD, Roche and Takeda and support for meeting attendance from Bristol Myers Squibb, Boehringer Ingelheim, Roche and Pfizer. All remaining authors have declared no conflicts of interest. All authors read and approved the final manuscript.